利培酮市場 - 全球產業規模、佔有率、趨勢、機會和預測，按給藥途徑、按應用、按最終用戶、按地區、按競爭進行細分，2020-2030F

2024 年全球利培酮市場價值為 6,057.5 億美元，預計在預測期內將實現令人印象深刻的成長，到 2030 年的複合年成長率為 5.10%。 全球利培酮市場是製藥業的關鍵領域，其促進因素是對有效治療精神疾病的需求。利培酮是一種抗精神病藥物，在治療精神分裂症、躁鬱症和某些情緒障礙等疾病方面發揮重要作用。

主要市場促進因素

精神疾病盛行率上升

主要市場挑戰

監管障礙和安全問題

主要市場趨勢

更重視心理健康意識和治療

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：利培酮市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依給藥途徑（注射、口服、腸胃外）
  • 按應用（精神分裂症、躁鬱症、自閉症相關易怒症、其他）
  • 按最終使用者（醫院、家庭護理、專科診所、門診手術中心等）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第 6 章：北美利培酮市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第 7 章：歐洲利培酮市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太地區利培酮市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美利培酮市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲利培酮市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 13 章：全球利培酮市場：SWOT 分析

第 14 章：波特五力分析

第 15 章：競爭格局

• Otsuka Pharmaceutical Co., Ltd
• AbbVie Inc
• Dr. Reddy's Laboratories Ltd
• Pfizer Inc
• Endo International plc
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd
• Viatris Inc
• Novartis AG
• Lupin Limited

第 16 章：策略建議

第17章 關於出版商,免責事項

Global Risperidone Market was valued at USD 605.75 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.10% through 2030. The global Risperidone market is a crucial segment of the pharmaceutical industry, driven by the demand for effective treatments of psychiatric disorders. Risperidone, an antipsychotic medication, plays a central role in managing conditions like schizophrenia, bipolar disorder, and certain mood disorders.

Key Market Drivers

Rising Prevalence of Mental Health Disorders

The rising prevalence of mental health disorders is a significant driver of the global Risperidone market, influencing demand, market expansion, and investment in mental health treatments. Risperidone, an antipsychotic medication primarily used to treat conditions such as schizophrenia, bipolar disorder, and irritability associated with autism, has seen increased adoption due to the growing burden of mental health issues worldwide. Mental health disorders, including schizophrenia, bipolar disorder, and autism spectrum disorders, are becoming more prevalent globally due to factors such as urbanization, lifestyle changes, stress, and greater awareness and diagnosis of these conditions. According to the World Health Organization (WHO), Approximately 1 in 4 of the global population will experience mental or neurological disorders at some stage in their lives. Currently, around 450 million individuals are affected by these conditions, making mental health disorders one of the primary contributors to ill-health and disability worldwide. Increased awareness campaigns and educational initiatives by governments, healthcare organizations, and advocacy groups have reduced the stigma surrounding mental health issues. As a result, more individuals are seeking diagnosis and treatment, leading to higher prescription rates of medications like Risperidone. This cultural shift has expanded the addressable market for antipsychotic drugs, driving growth in the Risperidone market.

Key Market Challenges

Regulatory Hurdles and Safety Concerns

The pharmaceutical industry operates within a heavily regulated framework, and Risperidone is no exception. Risperidone, like all medications, undergoes rigorous safety evaluations. Concerns about side effects, particularly metabolic and neurological issues, have led to increased scrutiny. Regulatory bodies often require pharmaceutical companies to update safety labels or provide additional warnings. As Risperidone loses patent protection in various regions, generic versions become available. Generic competition can lead to price erosion, reducing the revenue potential for branded Risperidone. These dynamic challenges market growth, as lower prices may affect profitability.

Key Market Trends

Increasing Focus on Mental Health Awareness and Treatment

Governments, international organizations, and healthcare advocacy groups have launched global mental health initiatives. These programs aim to raise awareness, reduce stigma, and improve access to mental health treatment. As a result, more individuals are seeking help for psychiatric disorders, driving the demand for medications like Risperidone. The integration of telehealth and digital mental health services has expanded access to psychiatric care. Remote consultations and telemedicine platforms facilitate diagnosis and treatment, including the prescription of Risperidone. This trend has gained further prominence during the COVID-19 pandemic. A shift towards community-based mental health services ensures that individuals have easier access to care. This trend promotes early diagnosis and treatment, leading to increased utilization of psychiatric medications like Risperidone.

Key Market Players

• Otsuka Pharmaceutical Co., Ltd
• AbbVie Inc
• Dr. Reddy's Laboratories Ltd
• Pfizer Inc
• Endo International plc
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd
• Viatris Inc
• Novartis AG
• Lupin Limited

Report Scope:

In this report, the Global Risperidone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Risperidone Market, By Route Of Administration:

• Injectable
• Oral
• Parenteral

Risperidone Market, By Application:

• Schizophrenia
• Bipolar Disorder
• Irritability Associated with Autistic Disorder
• Others

Risperidone Market, By End-Users:

• Hospitals
• Homecare
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Risperidone Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Risperidone Market.

Available Customizations:

Global Risperidone market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Risperidone Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route Of Administration (Injectable, Oral, Parenteral)
  • 5.2.2. By Application (Schizophrenia, Bipolar Disorder, Irritability Associated with Autistic Disorder, Others)
  • 5.2.3. By End-Users (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Risperidone Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Risperidone Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Risperidone Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Risperidone Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Risperidone Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Risperidone Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Risperidone Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Risperidone Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. France Risperidone Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route of Administration
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Risperidone Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Risperidone Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Risperidone Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Risperidone Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Risperidone Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Risperidone Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route of Administration
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Risperidone Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route of Administration
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Risperidone Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Risperidone Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Risperidone Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Risperidone Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Risperidone Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Risperidone Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Risperidone Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Risperidone Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Risperidone Market: SWOT Analysis

14. Porter's Five Forces Analysis

15. Competitive Landscape

• 15.1. Otsuka Pharmaceutical Co., Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Product & Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Financials (If Listed)
  • 15.1.5. Key Personnel
  • 15.1.6. SWOT Analysis
• 15.2. AbbVie Inc
• 15.3. Dr. Reddy's Laboratories Ltd
• 15.4. Pfizer Inc
• 15.5. Endo International plc
• 15.6. Teva Pharmaceutical Industries Ltd
• 15.7. Sun Pharmaceutical Industries Ltd
• 15.8. Viatris Inc
• 15.9. Novartis AG
• 15.10.Lupin Limited

16. Strategic Recommendations

17. About Us & Disclaimer